Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy

Table 2 Posterior probability of non-inferiority for FF/VI 100/25 mcg versus other relevant ICS/LABA* (full covariate model)

A: change from baseline FEV ₁
Treatment	Comparator	Mean difference, L (95% CrI)	Probability of non-inferiority margin (change from baseline)
			50 mL
FF/VI 100/25	FP/SAL 500/50	0.023 (−0.002, 0.048)	>99%
FF/VI 100/25	BUD/FORM 400/12	0.027 (−0.007, 0.061)	>99%
B: annual rate of moderate/severe exacerbations ^†
Treatment	Comparator	Rate ratio (95% CrI)	Probability of non-inferiority margin (event rate ratio)
			0.10	0.20
FF/VI 100/25	FP/SAL 500/50	0.925 (0.451, 1.734)	73%	80%
FF/VI 100/25	BUD/FORM 400/12	0.866 (0.396, 1.664)	77%	84%
C: change from baseline SGRQ Total score
Treatment	Comparator	Mean difference, units (95% CrI)	Probability of non-inferiority margin (units)
			2	3
FF/VI 100/25	FP/SAL 500/50	−1.321 (−3.955, 1.313)	99%	>99%
FF/VI 100/25	BUD/FORM 400/12	−0.964 (−3.897, 1.970)	98%	>99%

Note: All stated nominal doses are mcg.
BUD = budesonide, Crl = credible interval, FORM = formoterol, FEV₁ = forced expiratory volume in one second, FF = fluticasone furoate, FP = fluticasone propionate, S = salmeterol, SGRQ = St George’s Respiratory Questionnaire, VI = vilanterol.
*Other relevant ICS/LABA: FP/SAL 500/50 mcg and BUD/F 400/12 mcg.
†For studies in which patients were required to have an explicit exacerbation history at entry.

ISSN: 1465-993X